Spryson America Inc

Spryson (formerly Neurolign Technologies) is a world leader in neuro-functional monitoring and AI-driven eye-tracking diagnostics. The company specializes in non-invasive neurological assessment technology designed to detect and monitor neurodegenerative diseases, with particular focus on Parkinson's disease and traumatic brain injury/concussion detection. NeuroAI is their flagship platform that combines advanced eye-tracking with proprietary biomarkers and predictive analytics to enable earlier diagnosis, progression monitoring, and treatment optimization. The company has applied for FDA Breakthrough Device Status for their PD-Check technology. Spryson's approach emphasizes accessibility, bringing sophisticated neurological diagnostic capabilities to clinical institutions, research organizations, and consumer wellness applications. Their technology captures subtle neurological markers—including oculomotor responses, vestibular function, reaction time, and cognitive measures—that traditional assessment methods miss, delivering real-time objective data to clinicians for enhanced diagnostic accuracy and decision support.